A plastic material for extended release of a bio-active agent, the plastic material comprising a structural polymer, at least one bio-active ingredient embedded within the structural polymer as solid islands, a liquid binding material embedded within the structural polymer as granules, and a carrier liquid absorbed within the liquid-absorbent material. The carrier liquid may be sufficiently non-compatible with the structural polymer so that at least a portion of the carrier liquid is released from the liquid-absorbent material through the structural polymer to an outer surface of the plastic material over a period of time, such as a week or more, a month or more, or about three months. The bio-active agent comprised in the at least one bio-active ingredient may be sufficiently soluble in the carrier liquid at room or body temperature so that the carrier liquid released to the outer surface comprises the bio-active agent in solution.

The present invention relates to a collar for non-human animals, preferably for companion animals, comprising a polymeric matrix and a lipid extract comprising sphingomyelins. It also refers to the collar for use as a medicine, particularly for use as an adjuvant and for use in the treatment or prevention of atopic dermatitis or allergic dermatitis, as well as in restoring the integrity of the skin during or after an atopic dermatitis or an allergic dermatitis, increasing the hydration and flexibility of the skin, facilitating skin regeneration or reducing itching of the skin.

The present invention relates to a formulation or composition for the treatment, repair, formation or regeneration of bone tissue in a subject, comprising Histatin-1 or its derivatives. The present invention also relates to a biomaterial comprising Histatin-1 or its derivatives in a biocompatible material, and a method for the treatment, repair, formation or regeneration of bone tissues in a subject comprising administering to the subject a therapeutically effective amount of Histatin-1 or its derivatives.

The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-κB-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.

A therapeutic hoof treatment composition includes clay, copper sulfate, zinc oxide, triple antibiotic ointment, Tea Tree oil, Clotrimazole cream, and water.

The invention relates to compositions for use in the treatment or prevention of pathogenic infections, rosacea, eczema and psoriasis in humans or animals. The compositions of the invention are also useful in the healing of wounds in a human or animal, and for killing or inactivating viruses on a surface.

Compositions and methods of using them to protect an animal cell or tissue from a microbial pathogen are described. The compositions can include one or more natural oils or extracts comprising a therapeutically active compound to protect the cell or tissue of the animal from the microbial pathogen by direct inactivation of the microbial pathogen or by blocking the microbial pathogen entrance to the animal cell or tissue. Oil macerates that include a therapeutically active compound extracted from plants are also described.

A composition for treating skin wounds of an individual is disclosed. The composition is an extract that contains Zinc Gluconate, Lysine, Taurine, Potassium Gluconate, Carboxy Methyl Cellulose, Glycerin, Allantoin, water, Hydrogen chloride (HCl), Lidocaine, Niacin, Valine, L-Isoleucine, Proline, L-Arginine, Threonine, Glutamine, Histidine, Serine, Asparagine, Tyrosine, Cysteine, and pentapeptide for example, Enkephalin. The composition could be applied to the affected skin for effectively treating skin wounds, reducing expression lines, and relaxing muscle contractions, thereby reducing skin wrinkles, and smoothening skin. The composition is provided in at least any one or more forms include a gel, a spray, liquid, lotion, and a cream. The composition maintains a pH balance ranges from about 6.5 to 7.5.

There is provided a pharmaceutical formulation comprising an anticholinergic agent and a ternary solvent comprising 5% to 15% v/v glycol, 60% to 70% v/v alcohol and 5% to 20% v/v water. There is also provided a method of preparing the pharmaceutical formulation as disclosed herein, comprising the step of mixing the anticholinergic agent to a mixture containing alcohol, glycol, water, humectant and pH buffering agent at room temperature. There is also provided a method of inhibiting non-pathological body malodour in a mammal. There is also provided a method of treating apocrine secretion causing odour and reduction of microbial overgrowth in a mammalian subject, and uses of a pharmaceutical formulation.

The present invention relates to pharmaceutical compositions for topical use comprising a corticosteroid and an insecticide selected from pyrethrin or a synthetic pyrethroid insecticide. Methods for their use in treating allergic dermatitis, particularly insect bite hypersensitivity, in animals using the compositions of the invention are also described